<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325685</url>
  </required_header>
  <id_info>
    <org_study_id>SGDC-VAP-1</org_study_id>
    <nct_id>NCT04325685</nct_id>
  </id_info>
  <brief_title>The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia</brief_title>
  <acronym>SGDC-VAP</acronym>
  <official_title>The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia and Associated Microbiomes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oropharynx is the main source of pathogen microorganisms for the ventilator - associated
      pneumoniae. As known bacteriophages can eliminate different pathogen microorganisms or reduce
      a degree of a pathogen's colonization. The research team is considering that oropharyngeal
      decontamination with bacteriophages can prevent the developing of the ventilator - associated
      pneumoniae. There will be three groups in this investigation: placebo, antiseptic drug
      (Octenisept) and bacteriophage (Sexthaphag).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ventilator-associated pneumonia (VAP)</measure>
    <time_frame>Change from Baseline CPIS at 14 days</time_frame>
    <description>CPIS is using for diagnosis the VAP, if CPIS equal or more 6, the VAP will be confirmed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changing of oral and lung microbiomes</measure>
    <time_frame>Change from Baseline Microbiology researching at 14 days</time_frame>
    <description>Microbiology researching samples from oral cavity and trachea. The Gram positive and Gram negative aerobes and anaerobes will be assessed with observing Colony Form Unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction</measure>
    <time_frame>Change from Baseline Sequential Organ Function Assessment at 14 days</time_frame>
    <description>Sequential Organ Function Assessment (SOFA) will be using for assessment organ dysfunction Patient examination with Sequential Organ Function Assessment (SOFA). If Sequential Organ Function Assessment more then 2 points Organ dysfunction is present. The hirher value is equal worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of C - reactive protein (CRP)</measure>
    <time_frame>Change from Baseline CRP at 14 days</time_frame>
    <description>Biomarker of the VAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Procalcitonin (PCT)</measure>
    <time_frame>Change from Baseline PCT at 14 days</time_frame>
    <description>Biomarker of the VAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Mortality</measure>
    <time_frame>Change from Baseline PCT at 28 days</time_frame>
    <description>Mortality for 28 days of a hospitalization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Trauma Injury</condition>
  <condition>Brain Injuries</condition>
  <condition>Abdominal Sepsis</condition>
  <condition>Pancreatitis</condition>
  <condition>Meningitis</condition>
  <condition>Encephalitis</condition>
  <condition>Seizures</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiseptic (Octenisept) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacteriophage (Sextaphag) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiseptic Solution</intervention_name>
    <description>Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation</description>
    <arm_group_label>Antiseptic (Octenisept) group</arm_group_label>
    <other_name>Octenisept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacteriophage</intervention_name>
    <description>Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation</description>
    <arm_group_label>Bacteriophage (Sextaphag) group</arm_group_label>
    <other_name>Sextaphag</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - invasive mechanical ventilation beyond 48 hours

        Exclusion Criteria:

          -  hospital - acquired pneumonia

          -  community - acquired pneumoniae

          -  BMI &gt; 35 kg/cm2

          -  pregnancy

          -  tracheostomy

          -  reintubation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Budgetary Healthcare Institution of Arkhangelsk Region &quot;Severodvinsk City Clinical Emergency Hospital # 2&quot;</name>
      <address>
        <city>Severodvinsk</city>
        <state>Arkhangelsk Region</state>
        <zip>164500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern State Medical University</investigator_affiliation>
    <investigator_full_name>Vsevolod V. Kuzkov</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
    <mesh_term>Octenidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

